PMID- 10720072
OWN - NLM
STAT- MEDLINE
DCOM- 20000330
LR  - 20211203
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 85
IP  - 3
DP  - 2000 Mar
TI  - Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, 
      DQB1*0602: identification by the Diabetes Prevention Trial-type 1.
PG  - 1255-60
AB  - The presence of human leukocyte antigen (HLA) haplotype DQA1*0102, DQB1*0602 is 
      associated with protection from type 1 diabetes. The Diabetes Prevention 
      Trial-type 1 has identified 100 islet cell antibody (ICA)-positive relatives with 
      this protective haplotype, far exceeding the number of such subjects reported in 
      other studies worldwide. Comparisons between ICA+ relatives with and without 
      DQB1*0602 demonstrated no differences in gender or age; however, among racial 
      groups, African-American ICA+ relatives were more likely to carry this haplotype 
      than others. The ICA+ DQB1*0602 individuals were less likely to have additional 
      risk factors for diabetes [insulin autoantibody (IAA) positive or low first phase 
      insulin release (FPIR)] than ICA+ relatives without DQB1*0602. However, 29% of 
      the ICA+ DQB1*0602 relatives did have IAA or low FPIR. Although half of the ICA+ 
      DQB1*0602 relatives had a high risk second haplotype, this was not associated 
      with the additional risk factors for diabetes. Hispanic ICA+ individuals with 
      DQB1*0602 were more likely to be IAA positive or to have low FPIR than other 
      racial groups. In conclusion, the presence of ICA in the relatives described here 
      suggests that whatever the mechanism that protects DQB1*0602 individuals from 
      diabetes, it is likely to occur after the diabetes disease process has begun. In 
      addition, there may be different effects of DQB1*0602 between ethnic groups.
FAU - Greenbaum, C J
AU  - Greenbaum CJ
AD  - Department of Veterans Affairs, Puget Sound Health Care System, and the 
      Department of Medicine, University of Washington, Seattle 98108, USA.
FAU - Schatz, D A
AU  - Schatz DA
FAU - Cuthbertson, D
AU  - Cuthbertson D
FAU - Zeidler, A
AU  - Zeidler A
FAU - Eisenbarth, G S
AU  - Eisenbarth GS
FAU - Krischer, J P
AU  - Krischer JP
LA  - eng
GR  - UC4 DK117009/DK/NIDDK NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Autoantibodies)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ alpha-Chains)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQA1 antigen)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (Insulin)
RN  - 0 (islet cell antibody)
SB  - IM
MH  - Adult
MH  - Aging/physiology
MH  - Autoantibodies/analysis/*genetics
MH  - Diabetes Mellitus, Type 1/genetics
MH  - Family
MH  - Female
MH  - Genetic Testing
MH  - HLA-DQ Antigens/*analysis/*genetics
MH  - HLA-DQ alpha-Chains
MH  - HLA-DQ beta-Chains
MH  - Haplotypes
MH  - Humans
MH  - Insulin/metabolism
MH  - Islets of Langerhans/*immunology/physiology
MH  - Male
MH  - Racial Groups
MH  - Risk Assessment
MH  - Sex Characteristics
EDAT- 2000/03/17 09:00
MHDA- 2000/04/01 09:00
CRDT- 2000/03/17 09:00
PHST- 2000/03/17 09:00 [pubmed]
PHST- 2000/04/01 09:00 [medline]
PHST- 2000/03/17 09:00 [entrez]
AID - 10.1210/jcem.85.3.6459 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2000 Mar;85(3):1255-60. doi: 10.1210/jcem.85.3.6459.